VIDEO: Patients with severe DME benefit from high-dose aflibercept
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Deepak Sambhara, MD, discusses central retinal thickness in patients with diabetic macular edema.
Sambhara used data from the phase 2/3 PHOTON study, which investigated aflibercept 8 mg in patients with diabetic macular edema, to track patients’ treatment journey, with baseline central retinal thickness as a surrogate for disease severity.
“Folks receiving 8 mg aflibercept who have the most swollen and presumably most diseased retinas and more circulating VEGF in their system really required that additional boost, that additional amount of VEGF suppression that 8 mg affords you in order to increase durability and maintain anatomy for longer periods,” Sambhara said.
Collapse
Sambhara D. Impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macula edema (DME): Post hoc analysis of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about